Affiliation:
1. Department of Oncology, Vall d'Hebron University Hospital, Barcelona, Spain
Abstract
Learning Objectives
After completing this course, the reader will be able to: Describe the mechanism of action of epothilones and the different epothilone analogs in clinical development.Discuss the current status and the results of phase II trials with epothilone analogs in metastatic breast cancer.Explain why epothilone may have utility in combination with other cytotoxic chemotherapeutic agents for treating metastatic breast cancer.
CME Access and take the CME test online and receive 1 AMA PRA Category 1 Credit™ at CME.TheOncologist.com
Publisher
Oxford University Press (OUP)
Reference59 articles.
1. Cancer statistics, 2005;Jemal;CA Cancer J Clin,2005
2. Chemotherapy of metastatic breast cancer: What to expect in 2001 and beyond;Esteva;The Oncologist,2001
3. Taxanes in combined-modality therapy for solid tumors;Choy;Oncology (Williston Park),1999
4. Epothilones: Mechanism of action and biologic activity;Goodin;J Clin Oncol,2004
5. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action;Bollag;Cancer Res,1995
Cited by
124 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献